<?xml version="1.0"?>
<rss version="0.91">
<channel>
 <title>Drug Discovery -
Drug Discovery World</title>
 <link>http://www.ddw-online.com</link>
 <description/>
 <language>en</language> 
 <lastBuildDate>Sun, 07 Mar 2010 08:12 +0000</lastBuildDate>
 
 
 <item>
 <link>http://www.ddw-online.com/drug_discovery/205536/progress_in_the_implementation_of_labelfree_dectetion_part_1_cellbased_assays.html</link>
 <title>Progress in the implementation of Label-Free Dectetion - part 1: cell-based assays</title>
 <pubDate>Thu, 19 Feb 2009 14:25 +0000</pubDate>
 <description><![CDATA[Overall it remains unclear whether label-free will break into main stream cell-based lead discovery or will mostly fill the gaps that other technologies do less well?]]></description>
</item>
 
 <item>
 <link>http://www.ddw-online.com/drug_discovery/258437/natural_product_pharmaceuticals_the_third_generation.html</link>
 <title>Natural product pharmaceuticals - the third generation</title>
 <pubDate>Thu, 28 May 2009 16:45 +0000</pubDate>
 <description><![CDATA[Compounds derived from natural products have made a big impact on the pharmaceutical industry. Of the 1,010 NCEs approved between January 1981 and June 2006, 43 were unaltered natural products (NPs) and a further 232 (23%) were second generation NP derivatives1.]]></description>
</item>
 
 <item>
 <link>http://www.ddw-online.com/drug_discovery/236235/growing_interest_in_outsourcing_ion_channel_services.html</link>
 <title>Growing Interest in Outsourcing Ion Channel Services</title>
 <pubDate>Thu, 16 Apr 2009 14:38 +0000</pubDate>
 <description><![CDATA[Significant demand now exists in Pharma and Biotech to access ion channel testing services and this is reflected by the number and the variety of service offerings.]]></description>
</item>
 
 <item>
 <link>http://www.ddw-online.com/drug_discovery/239329/challenges_in_transferring_bioanalytical_methods.html</link>
 <title>Challenges in transferring bioanalytical methods</title>
 <pubDate>Wed, 22 Apr 2009 13:55 +0000</pubDate>
 <description><![CDATA[Drug development is arduous and expensive with any delay to market resulting in significant financial impact. Delays at any stage of the process cause challenges to programmes, however, some are easier to predict and plan for than others.]]></description>
</item>
 
 <item>
 <link>http://www.ddw-online.com/drug_discovery/312837/the_role_of_thorough_qt_testing_in_managing_drug_development.html</link>
 <title>The role of Thorough QT testing in managing drug development</title>
 <pubDate>Wed, 02 Sep 2009 10:12 +0000</pubDate>
 <description><![CDATA[With few exceptions, all compounds being submitted to the Food and Drug Administration (FDA) for approval in the United States will require an assessment of QT prolongation, either by a standard Thorough QT/QTc study, or a similar study modified to fit the safety profile of the compound and indicated patient population. ]]></description>
</item>
 </channel>
</rss>